Diagnostic Kits/Page for Joint Creation of Blog Post

Blog Post

• Introduction to Our Research
  • The field of Biotechnology including Genomics and Proteomics is a critical US industry. The emerging research in the genetic diagnostic kits presents unique challenges in intellectual property (IP). Changes in laboratory research due to actual or anticipated patent or license enforcement could signal the failure of intellectual property to spur the innovation these protections are intended to promote. It is these issues that are at the centre of our research under the Industrial Cooperation Project at the Berkman Centre at Harvard University. This research is part of a broader project being led by Prof. Yochai Benkler. In the research, we are seeking to understand the approaches to innovation with genetic diagnostic kits looking specifically at barriers to use and innovation.
• 2 paragraphs on the field and our focus (Mac)
• The market and the commons
  • One of the dangers present in the patent protections surrounding genetic diagnostic tests is that basic scientific knowledge is being protected. This is part of a larger misled belief that public support of open science is less necessary as science becomes a task of the private sector and focused on addressing specific society needs (see Nelson, 2003). This use-inspired basic research has its benefits but science is a largely unpredictable enterprise and it's evolution requires the work of many people. This view of science requires widespread access to basic research. An influential discussion regarding the concerns about the affects of patents and licensing on diagnostic test has been the article titled Diagnostic testing fails the test: The pitfalls of patents are illustrated by the case of hemochromatosis published in Nature in 2002. The primary concerns highlighted by this study were the possible delays in publication and the affect on cost and availability of clinical diagnostic testing.
• Relevent Caselaw
  • The most important legal protections of genetic diagnostic kits are trade secret and patents. While trade secret plays a large role, studying it is difficult because most of the information is not public. Patents are public information and they have been the focus of our current research. The gene-disease associations that researchers study can be developed into a genetic diagnostic kit and these tests are often covered by patents. Our research aims to discover the role patents play in genetic diagnostic kit development and commercialization. The Bilski case “machine-or-transformation” test provides patent protection for genetic diagnostic kits if the machine or transformation used in the claimed process would "not merely be insignificant extra-solution activity." In re Bilski, 545 F.3d 943, 962 (Fed. Cir. 2008) (en banc), cert. granted, 129 S. Ct. 2735 (2009). The recent Prometheus Labs case investigate the bounds of the Bilski case by looking specifically at a transformation that takes place within the human body. Prometheus Labs., Inc. v. Mayo Collaborative Servs., No. 2008-1403, slip op. at 8 (Fed. Cir. Sept. 16, 2009).[[1]] This broad interpretation of a transformation has important implications about the scope of protection that genetic diagnostic kits will receive. The finality of this analysis will be determined when the Supreme Court reviews Bilski.
• The Role of Universities
  • Research universities are active in DNA patenting and licensing so technology transfer is central to how important developments in diagnostic tests are licensed. Patenting or research is encouraged by the Bayh-Dole Act which deals specifically with federal government-funded research but has more widely effected the patenting procedure of all university research. If a university elects to hold title to the federally funded invention it is obligated to patent and attempt to commercialize the invention. A theoretical limit on this a set of "march in rights" held by the funding agency which would allow it to grant further licenses but this right is constrained by a necessity analysis under the statute and until now the rights have only been requested or threatened but never used. Another source of licensing restriction can come from the source of the funds. For instance, the National Institutes of Health is a major source of funding and their funding power has allowed them to create guidelines on how to license research resources arising from the funded research.
• Possible Solutions
  • One solution to potential patent problem developing is the use of patent pools or patent clearinghouses (see Verbeure, B. et al., 2006). One important limitation to this approach is that the biotechnology industry lacks standard-driven incentives found in other industries that benefit from patent pools. The scope of patent protection is currently being questioned by the Bilski case but a more limited interpretation of patentable subject matter would allow more basic research to remain available for all scientists to build upon without restriction. Altering the scope of patent protection is only a partial solution but requiring more substantial transformations and the expanding the meaning of natural could be key to limiting the creation of a patent thicket surrounding the basic research relied on in genetic diagnostic kit development. Lastly, the licensing behavior that gives preference to reasonable pricing and non-exclusive right could have a significant impact. The march in rights under Bayh-Dole have never been carried out but federal agencies funding genetic diagnostic kit research should provide licensing guidelines and resort to utilizing march in rights if they are necessary to promote

Check https://cbr-diagnostics.etherpad.com/1 for current progress & collab editing